Reposted by @dfcicancerbio.bsky.social
A new study led by Dipanjan Chowdhury, PhD, co-director of our Center for BRCA and Related Genes, uncovers why some cancers resist PARP inhibitors. The findings could help guide more personalized treatment strategies.
Learn more about the study: bit.ly/4ko5CAq
bit.ly
Double Negative in Cells Could Undermine PARP Inhibitors
Published: June 10, 2025Updated: June 11, 2025Written by: Beth DoughertyThere are two ways to fix things: the quick way and the careful one. In cancer, cells with BRCA1 mutations tend to choose the quick fix, leaving them vulnerable to medicines like PARP inhibitors. PARP inhibitors cause DNA to break. When broken strands and sketchy repairs ... Read more